Journal
JOURNAL OF IMMUNOLOGY
Volume 209, Issue 1, Pages 157-170Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.2200192
Keywords
-
Categories
Funding
- Craig H. Neilsen Foundation [457267, 647110, 596764, 457328]
- Ohio State University Presidential Postdoctoral Fellowship
- Wings for Life
- National Institute of Neurological Disorders and Stroke/National Institutes of Health [R01NS099532, R01NS083942, R35NS111582, R01NS118200]
- National Institute of Disability, Independent Living and Rehabilitation Research [90SI5020]
- Ray W. Poppleton Endowment
- European Union (EU Era Net-Neuron Program, SILENCE) [01EW170A]
- William E. Hunt and Charlotte M. Curtis Endowment
Ask authors/readers for more resources
Pulmonary infection is a common and serious complication after spinal cord injury (SCI). This study shows that SCI not only impairs the immune system in the lung, but also decreases the tissue-specific defense mechanisms against infection. Moreover, the current drug AMD3100 is only partially effective in overcoming this immune suppression. Novel strategies are needed to prevent lung infection after SCI.
Pulmonary infection is a leading cause of morbidity and mortality after spinal cord injury (SCI). Although SCI causes atrophy and dysfunction in primary and secondary lymphoid tissues with a corresponding decrease in the number and function of circulating leukocytes, it is unknown whether this SCI-dependent systemic immune suppression also affects the unique tissue-specific antimicrobial defense mechanisms that protect the lung. In this study, we tested the hypothesis that SCI directly impairs pulmonary immunity and subsequently increases the risk for developing pneumonia. Using mouse models of severe high-level SCI, we find that recruitment of circulating leukocytes and transcriptional control of immune signaling in the lung is impaired after SCI, creating an environment that is permissive for infection. Specifically, we saw a sustained loss of pulmonary leukocytes, a loss of alveolar macrophages at chronic time points postinjury, and a decrease in immune modulatory genes, especially cytokines, needed to eliminate pulmonary infections. Importantly, this injury-dependent impairment of pulmonary antimicrobial defense is only partially overcome by boosting the recruitment of immune cells to the lung with the drug AMD3100, a Food and Drug Administration-approved drug that mobilizes leukocytes and hematopoietic stem cells from bone marrow. Collectively, these data indicate that the immune-suppressive effects of SCI extend to the lung, a unique site of mucosal immunity. Furthermore, preventing lung infection after SCI will likely require novel strategies, beyond the use of orthodox antibiotics, to reverse or block tissue-specific cellular and molecular determinants of pulmonary immune surveillance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available